NEW YORK – Viome Life Sciences said Tuesday that it has raised $25 million in a Series D funding round.
Investors for the round included Khosla Ventures, Bold Capital, WRG Ventures, Marc Benioff, and other existing investors. The firm will use the money to help launch the company's diagnostic division, expand its testing menu, and hire Kal Raman as the firm's chief operating officer to lead those projects.
The firm noted that Raman previously worked as a senior VP of non-media business at Amazon, chief digital officer at Samsung, and chief operating officer at Groupon.
Viome said that it plans to expand its diagnostic offerings beyond its tests for oral and throat cancers, and Raman will lead efforts to develop tests for the early detection of other cancers, chronic diseases, and aging-related conditions. The firm said that it is positioned to launch a suite of new tests, such as tests for gut health conditions including irritable bowel syndrome and inflammatory bowel disease.
Viome recently said that it inked a distribution deal with Henry Schein for its Oral Health Pro With CancerDetect laboratory-developed test that is used for the detection of oral and throat cancers. Using RNA sequencing and AI to measure gene expression of the oral microbiome and human cells in saliva, the assay identifies early biomarkers associated with oral and throat cancer.
The firm also said last year that it raised $86.5 million in an oversubscribed Series C round that would support the development of the firm's testing portfolio and expansion into retail sales.